Bio Path reported 677K in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Baxter International USD 78M 20M Mar/2026
Bio Path 677K 547K Mar/2026
Cipla INR 170.3M 39M Jun/2026
Compugen USD 1.35M 399K Mar/2026
CSL USD 215M 111M Dec/2025
Grifols EUR 156.07M 31.46M Sep/2025
Karyopharm Therapeutics USD 12.55M 66K Mar/2026